1. Home
  2. PSNL vs ALT Comparison

PSNL vs ALT Comparison

Compare PSNL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PSNL
  • ALT
  • Stock Information
  • Founded
  • PSNL 2011
  • ALT 1997
  • Country
  • PSNL United States
  • ALT United States
  • Employees
  • PSNL N/A
  • ALT N/A
  • Industry
  • PSNL Medical Specialities
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • PSNL Health Care
  • ALT Health Care
  • Exchange
  • PSNL Nasdaq
  • ALT Nasdaq
  • Market Cap
  • PSNL 460.7M
  • ALT 529.9M
  • IPO Year
  • PSNL 2019
  • ALT N/A
  • Fundamental
  • Price
  • PSNL $4.89
  • ALT $6.86
  • Analyst Decision
  • PSNL Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • PSNL 4
  • ALT 8
  • Target Price
  • PSNL $8.56
  • ALT $19.71
  • AVG Volume (30 Days)
  • PSNL 1.5M
  • ALT 2.7M
  • Earning Date
  • PSNL 02-26-2025
  • ALT 11-12-2024
  • Dividend Yield
  • PSNL N/A
  • ALT N/A
  • EPS Growth
  • PSNL N/A
  • ALT N/A
  • EPS
  • PSNL N/A
  • ALT N/A
  • Revenue
  • PSNL $87,489,000.00
  • ALT $52,000.00
  • Revenue This Year
  • PSNL $15.76
  • ALT N/A
  • Revenue Next Year
  • PSNL $4.90
  • ALT N/A
  • P/E Ratio
  • PSNL N/A
  • ALT N/A
  • Revenue Growth
  • PSNL 24.05
  • ALT N/A
  • 52 Week Low
  • PSNL $1.12
  • ALT $5.28
  • 52 Week High
  • PSNL $7.20
  • ALT $14.84
  • Technical
  • Relative Strength Index (RSI)
  • PSNL 45.39
  • ALT 41.92
  • Support Level
  • PSNL $5.22
  • ALT $6.19
  • Resistance Level
  • PSNL $5.50
  • ALT $7.83
  • Average True Range (ATR)
  • PSNL 0.57
  • ALT 0.41
  • MACD
  • PSNL -0.18
  • ALT -0.06
  • Stochastic Oscillator
  • PSNL 8.33
  • ALT 36.41

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: